Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort

• Autor(a) principal: Urueta-Robledo, Juan
• Data de Publicação: 2006
• Outros Autores: Ariza, Horacio, Jardim, José Roberto [UNIFESP], Caballero, Andres, Garcia-Calderon, Andres, Amabile-Cuevas, Carlos F., Hernandez-Oliva, Gerardo, Vivar-Orozco, Raul, MOX-CB Study Group
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1016/j.rmed.2006.01.013; http://repositorio.unifesp.br/handle/11600/29103
• topic: chronic bronchitis; moxifloxacin; levofloxacin

We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized to oral therapy with either moxifloxacin 400 mg once daily for 5 days or levofloxacin 500 mg once daily for 7 days. Clinical success was achieved in 201 out of 221 (91.0%) patients in the moxifloxacin group, and in 203 out of 216 (94.0%) in the levofloxacin group, indicating that moxifloxacin is equivalently effective to levofloxacin. Bacteriologic eradication or presumed eradication was also similar in the two treatment groups: 92.8% in the moxifloxacin group and 93.8% in the levofloxacin group. Nausea was the most common drug-related adverse event in each treatment group. the rate of discontinuation because of adverse events was very low (<= 2%). in conclusion, a 5-day course of moxifloxacin is clinically and bacteriologically equivalent to a 7-day course of levofloxacin in the treatment of patients with AECB. the short treatment duration with moxifloxacin may have compliance advantages over other currently used therapies in the 'real-Life' clinical setting. (c) 2006 Elsevier B.V. All rights reserved.